22 research outputs found

    Development of a Solid Dispersion of Nystatin with Maltodextrin as a Carrier Agent: Improvements in Antifungal Efficacy against Candida spp. Biofilm Infections

    Get PDF
    The aim of this study was to improve the treatment of Candida albicans biofilms through the use of nystatin solid dispersions developed using maltodextrins as a hyperosmotic carrier. Characterization studies by differential scanning calorimetry, X-ray diffraction, dissolution studies, and particle size analysis were performed to evaluate changes in nystatin crystallinity. Antifungal activity and anti-biofilm efficacy were assessed by microbiological techniques. The results for nystatin solid dispersions showed that the enhancement of antifungal activity may be related to the high proportions of maltodextrins. Anti-biofilm assays showed a significant reduction (more than 80%) on biofilm formation with SD-N:MD [1:6] compared to the nystatin reference suspension. The elaboration process and physicochemical properties of SD-N:MD [1:6] could be a promising strategy for treatment of Candida biofilms.Depto. de Farmacia Galénica y Tecnología AlimentariaFac. de FarmaciaTRUEMinisterio de Ciencia e Innovación [MICINU]Faculty of Pharmacy, University Complutense of Madrid [Research Group 910939]pu

    Self-Micellizing Technology Improves the Properties of Ezetimibe and Increases Its Effect on Hyperlipidemic Rats

    Get PDF
    The aim of this work was to develop ezetimibe self-micellizing solid dispersions using Kolliphor® RH40 (MS-K) as a surfactant incorporating ezetimibe (EZ) into the croscarmellose hydrophilic carrier. Different ezetimibe:Kolliphor® ratios were studied to select micellar systems that improve the dissolution properties of ezetimibe. The different formulations were characterized by means of solid state analysis by SEM, powder X-ray diffraction (PXRD), differential scanning calorimetry (DSC), and dissolution studies. These physicochemical studies showed a decrease from the crystalline structure of ezetimibe (EZ) to its amorphous state in the micellar systems (MS-K). A rapid dissolution profile was observed in these micellar systems compared to the drug raw material and physical mixture. Efficacy studies were conducted using a high-fat diet that induced hyperlipidemic rats. The micellar system selected (MS-K 1:0.75) revealed a significant improvement in serum levels of total cholesterol (TC), low-density lipoproteins (LDL), and triglycerides (TG) compared to ezetimibe raw material. The histopathological examination of liver tissue also showed that this micellar system exhibited more beneficial effects on liver steatosis compared to ezetimibe raw material (EZ-RM) and the high-fat diet group (HFD). This study suggests that EZ micellar systems using Kolliphor® RH40 could enhance the antihyperlipidemic effect of ezetimibe and reduce liver steatosis

    Estudio galénico de distintas formulaciones de ácido acetilsalicílico

    Get PDF
    El objeto de la presente memoria para optar al grado de doctor en farmacia, se centra en el estudio de distintas formulaciones de comprimidos de ácido acetil salicílico con tres acciones diferentes; analgésica, antirreumática y antitrombótica. Para ello se estudian distintos métodos analíticos de ácido acetil salicílico y ácido salicílico, seleccionando, según el tipo de ensayo, el método analítico más adecuado. En los estudios farmacotécnicos se evalúan unas 40 formulaciones, principalmente sus características de compresibilidad y de velocidad de disolución "in vitro", y se comparan con distintas especialidades farmacéuticas comercializadas. Se realiza un estudio de estabilidad química de alguna de estas formulaciones. en los estudios de gastrotoxicidad se evalúa la influencia del tamaño de partícula, velocidad de cesión y el uso de algunas sustancias gastroprotectoras. Por último, se seleccionan seis formulaciones de las que se estudia su biodisponibilidad relativa y su posible correlación "vitro-vivo

    Composición química IGF para el tratamiento y prevención de enfermedades neurodegenerativas

    Get PDF
    Traducción de Patente Europea E03744388 (fecha de solicitud, 21/02/2003).-- Prioridad: ES20020228200200491.-- Titulares: Consejo Superior de Investigaciones Científicas (CSIC), Universidad Complutense de Madrid (UCM).La invención se refiere a nuevas composiciones terapéuticas de administración lenta de IGF-I, a un procedimiento de preparación y obtención de las mismas y a su empleo para la elaboración de medicamentos para el tratamiento y prevención de enfermedades neurodegenerativas como, entre otras, la enfermedad de Alzheimer o la ataxia cerebelar.Estas composiciones se corresponden con microesferas de tamaño menor de 5 micrometros, entre otras características, y con cápsulas de implantación subcutánea.Peer reviewe
    corecore